



Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, January 16, 2025

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board

Agenda Item	Record	Notes																								
<p>1) Call to Order and Roll Call</p>	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Jennifer Wheeler called the meeting to order at 1:03 p.m. on January 16, 2025.</p> <p>Chairperson Wheeler took the roll.</p> <table border="0" style="width: 100%;"> <thead> <tr> <th></th> <th style="text-align: center;">Present</th> <th style="text-align: center;">Absent</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO**</td> <td style="text-align: center;"><input type="checkbox"/></td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td style="text-align: center;"><input checked="" type="checkbox"/></td> <td style="text-align: center;"><input type="checkbox"/></td> </tr> </tbody> </table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO**	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none"> • Duncan, Keiko, Pharm.D., Medicaid Pharmacy Director • Brown, Antonio, Chief of Pharmacy & DME • Palomino, Bonnie, Pharmacy Services Manager • Cabrera, Donna, Program Officer I • Driscoll, Lauren, Deputy Attorney General (DAG) <p>Prime Therapeutics Staff Present were as follows:</p> <ul style="list-style-type: none"> • Mishra, Raj, Pharm.D., Clinical Account Manager • Martinez, Chris, Sr. Business Analyst • Deoliveira, Brittany, Pharm.D., Clinical Account Manager
	Present	Absent																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Brain Le, DO**	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								

		<p>Managed Care Organization representatives present were as follows:</p> <ul style="list-style-type: none"> • Bitton, Ryan, Pharm.D., Health Plan of Nevada • Beranek, Tom, Pharm.D., Silver Summit Health Plan • Tran, Jimmy, Pharm.D., Molina Healthcare • Ahmed, Shadi, Pharm.D., Anthem <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.</p>												
<p>2) General Public Comment</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>													
<p>3) Administrative</p>														
<p>a) For Possible Action: Review and Approve Meeting Minutes from July 18, 2024.</p>	<p>Vice-Chair Neto Adeolokun moved to approve the minutes as presented, and Board Member Jessica Cate seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="594 1312 1381 1416"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

	<ul style="list-style-type: none"> • Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
<p>b) Status Update by DHCFP</p>	<p>Chief of Pharmacy and DME Antonio Brown provided an announcement.</p> <p>Good afternoon, everybody. For the record, my name is Antonio Brown. I am the Chief of Pharmacy Services and Durable Medical Equipment with DHCFP. Happy New Year to all of you. I am so excited that we could be here today and, first and foremost, I just want to thank the Board and its Members for all their commitment and active participation. Your dedication has been instrumental in many achievements over this past year, and it is vital to take a moment and celebrate all that we have accomplished here. Together, with your invaluable support, we have successfully held three DUR meetings last year in 2024. We were able to revise nearly 50 criteria. These efforts really reflect the shared commitment to Medicaid's mission to provide quality health care services to low income and in the most efficient manner while providing equal access to care at an affordable cost to the taxpayers.</p> <p>To highlight a few of the incredible contributions of our two new long-standing members, Doctor England has been serving on our board since 1992, bringing decades of wisdom and dedication to the table. And similarly, our board chair, Doctor Wheeler, who has been in that role since 2019, has been the guiding force steering us with vision and purpose. And most importantly, to each of our board members who play a critical part in our success of this board. None of our progress would have been possible without your engagement and tireless participation.</p> <p>As we look ahead into the year, I am filled with optimism and excitement to make collaboration our cornerstone working together to build our success and find innovative ways to serve the people in Nevada.</p> <p>On behalf of Nevada Medicare and all of those that we serve, I extend my deepest thanks to each of you and here is another year of</p>	

	<p>impactful work in medical success.</p> <p>Also, I am excited to announce that we have a new member joining our Medicaid pharmacy team, Donna Cabrera, who is our new Program Officer and will be taking over the Pharmacy Lock-In Program.</p> <p>To highlight a few changes that have taken place since our last meeting, the RSV coverage season did open up as of November 1, 2024, and it goes through March 31, 2024. We began accepting prior authorization as of October 21, 2024, for a date of services beginning in November 1, 2024. Effective September 26, 2024, we made some changes to our Diabetic Supplies Preferred Drug List. Full details can be found at nv.primetherapeutics.com.</p> <p>Lastly, I wanted to share is that we are actively recruiting for both SSSB and DUR board members. If you wish to nominate or know someone who may be interested, please share their CV to Rxinfo@dhcp.nv.gov. Thank you.</p>	
<p>4) Clinical Presentations</p>		
<p>a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Cayston (aztreonam).</p>		
<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Raj Mishra provided the clinical background and indications for Cayston.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder for Cayston.</p>	

	<ul style="list-style-type: none"> • Dr. Ryan Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Tom Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Jimmy Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Shadi Ahmed with Anthem, approved of the proposed criteria as presented. 																																	
<p>iii) Discussion by Board and review of utilization data.</p>	<p>Chairperson Jennifer Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																	
<p>iv) Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member David England moved to approve the criteria as presented by Prime Therapeutics and Vice-Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="594 950 1386 1242"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
<p>b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Ingrezza (valbenazine).</p>																																		

<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Precious Cagungun and Mandeep Sohal.</p>	
<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Ingrezza.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Ingrezza.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	
<p>iii) Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comment was made.</p>	
<p>iv) Proposed adoption of updated prior authorization criteria.</p>	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Chairperson Wheeler seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

	<table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
<p>c. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Benlysta (belimumab).</p>																																		
<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	
<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Benlysta.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Benlysta.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 																																	

iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comment was made.																																	
iv) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Board Member England seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table data-bbox="594 735 1386 1027"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Voydeya (danicopan) .																																		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.																																	

<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Voydeya.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Voydeya.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 																																	
<p>iii) Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Comment was made by Vice-Chair Adeolokun.</p>																																	
<p>iv) Proposed adoption of updated prior authorization criteria.</p>	<p>Vice Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Chairperson Wheeler seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="594 1170 1388 1464"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

<p>e. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Polyneuropathy of Hereditary Amyloidosis Agents.</p>		
<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Onpattro (patisiran) and Tegsedi (inotersen).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Onpattro and Tegsedi.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	
<p>iii) Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>Comment was made by Vice-Chair Adeolokun.</p>	
<p>iv) Proposed adoption of updated prior authorization criteria.</p>	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Chairperson Wheeler seconded the motion.</p>	

	<p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input checked="" type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table> <p>**Board Member Dr. Brian Le joined the meeting following the voting of Polyneuropathy of Hereditary Amyloidosis Agents. His attendance was also noted by Pharmacy Chief Antonio Brown for the record.</p>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
<p>f) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Xolremdi (mavorixafor).</p>																																		
<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	

<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Xolremdi.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Xolremdi.</p> <ul style="list-style-type: none">• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented.• Dr. Ahmed with Anthem, approved of the proposed criteria as presented.	
<p>iii) Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comment was made.</p>	

<p>iv) Proposed adoption of updated prior authorization criteria.</p>	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table border="0" data-bbox="579 448 1373 738"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
<p>g. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Duchenne Muscular Dystrophy Agents.</p>																																		
<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	

<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Agamree (vamorolone) and Duvyzat (givinostat).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Agamree and Duvyzat.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 																																	
<p>iii) Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comment was made.</p>																																	
<p>iv) Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member Crystal Castaneda moved to approve the criteria as presented by Prime Therapeutics, and Board Member Brian Le seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="594 1201 1386 1494"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

<p>h. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Respirator and Allergy Biologics.</p>		
<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Christie Bama.</p>	
<p>ii) Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Dupixent (dupilumab) and Fasentra (benralizumab).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Dupixent (dupilumab) and Fasentra (benralizumab).</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	

<p>iii) Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comment was made.</p>																																	
<p>iv) Proposed adoption of updated prior authorization criteria.</p>	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table data-bbox="594 699 1381 992"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															

<p>i. Criteria updates per Food and Drug Administration (FDA) Label expansions</p>		
<p>i) <u>Public comment</u> on clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Amy Hale.</p>	
<p>ii) Presentation of prior authorization updates</p>	<p>Dr. Mishra provided the criteria updates on Tymlos (abaloparatide), Linzess (linaclotide), Elevidys (delandistrogene moxeparvovec-rokl), Spravato (esketamine).</p>	
<p>j. Opioid Utilization Reports:</p> <p>i) Opioid Trends ii) Top Members iii) Top Prescribers iv) Top Pharmacies</p>	<ul style="list-style-type: none"> • Dr. Mishra presented opioid utilization reports. • Dr. Bitton presented opioid utilization reports. • Dr. Beranek presented opioid utilization reports. • Dr. Tran presented opioid utilization reports. • Dr. Ahmed presented opioid utilization reports. <p>Chairperson Wheeler asked for comments from Board Members regarding Opioid Reports. The Board discussed utilization and trends. No additional action taken or motions for investigative referrals.</p>	
<p>k. Standard DUR Reports:</p> <p>i) Top 10 Therapeutic Classes ii) ProDUR Paid Claims Savings Report iii) RetroDUR DUR Initiatives</p>	<ul style="list-style-type: none"> • Dr. Mishra presented Standard DUR Reports. • Dr. Bitton presented Standard DUR Reports. • Dr. Beranek presented Standard DUR Reports. • Dr. Tran presented Standard DUR Reports. • Dr. Ahmed presented Standard DUR Reports. 	

<p>I. Centers for Medicare and Medicaid Services (CMS) Annual Drug Utilization Review Surveys</p>	<ul style="list-style-type: none"> • Dr. Mishra presented highlights for Fee-for-Service Annual DUR Survey • Dr. Bitton presented highlights for Health Plan of Nevada Annual DUR Survey • Dr. Beranek presented highlights from SilverSummit Annual DUR Survey • Dr. Tran presented highlights from Molina Annual DUR Survey • Dr. Ahmed presented highlights from Anthem Annual DUR Survey 	
<p>m. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Physician Administered Drugs.</p>	<ul style="list-style-type: none"> • aflibercept • Bavencio (avelumab) • Beovu (brolucizumab-dbll) • bevacizumab • Darzalex (daratumumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Imfinzi (durvalumab) • Jemperli (dostarlimab-gxly) • Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • Ocrevus (ocrelizumab) • Opdivo (nivolumab) • paclitaxel albumin-bound • pemetrexed • ranibizumab • rituximab IV • immune globulin SC • Susvimo (ranibizumab) • Tecentriq (atezolizumab) • trastuzumab IV • Yervoy (ipilimumab) 	

<p>i) <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comments provided by Camille Kerr and Kathleen Teeterman.</p>	
<p>ii) Presentation of utilization and clinical information</p>	<p>Dr. Victoria Facchini reviewed the proposed criteria updates presented in the binder:</p> <ul style="list-style-type: none"> • aflibercept • Bavencio (avelumab) • Beovu (brolucizumab-dbll) • bevacizumab • Darzalex (daratumumab) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Imfinzi (durvalumab) • Jemperli (dostarlimab-gxly) • Keytruda (pembrolizumab) • Libtayo (cemiplimab-rwlc) • Ocrevus (ocrelizumab) • Opdivo (nivolumab) • paclitaxel albumin-bound • pemetrexed • ranibizumab • rituximab IV • immune globulin SC • Susvimo (ranibizumab) • Tecentriq (atezolizumab) • trastuzumab IV • Yervoy (ipilimumab) <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	

iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No Comments were made.																																	
iv) Proposed adoption of updated prior authorization criteria.	Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics and Chairperson Wheeler seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table border="0"> <thead> <tr> <th></th> <th>Yes</th> <th>No</th> <th>Abst.</th> </tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Crystal Castaneda, MD</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jessica Cate, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Dave England, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Brain Le, DO</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> <tr> <td>• Jim Tran, Pharm.D.</td> <td><input checked="" type="checkbox"/></td> <td><input type="checkbox"/></td> <td><input type="checkbox"/></td> </tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
5) Closing Discussion																																		
a. Public Comment	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.																																	
b. For Possible Action: Date and location of the next meeting.	Chairperson Wheeler stated the next meeting is scheduled for April 17, 2025. Location: Hilton Garden Inn Reno Meeting adjourned at 3:41 pm																																	

Attachment A – Members of the Public in Attendance

Kaiser, Alexandra	Garth Wright	Notetaker Sabrina
Sara Stolfus	Stephanie Kennedy	Jessica Czechowski
Crecco, Jason	Capperella, Olivia	Roa, Ryan A
Dube, Christine	Todd Estus	Robin Wells
Sabrina Schnur	Tray Abney	Alford, Angelo
Chris Johnson	Garcia, Kenneth	Pulver, Lisa
Stamatis, Brooke	Lynda Finch	Mandeep Sohal
Dana Pipkin	Camille Kerr	
Abraham, Stefanie	Precious Cagungun	
Cade Grogan	Shelly Nickerson	

Attachment B – Submitted Written Comment

None